EU Pharma Package: Key Takeaways for Clinical Evidence & JCA Strategy
Following the political agreement of 11 December 2025 on the EU Pharmaceutical Package, the summary...
Posts about
Full-Service
Preserving What Matters: How Institutional Knowledge Protects Value Through M&A
Mergers and acquisitions (M&As) are a defining feature of today’s biopharmaceutical landscape. As...
Strengthening Opportunities for Growth in the European Region
With the recent changes in clinical trial regulations and the growth of clinical trials in Europe,...Successful Full-Service, Randomized Pancreatic Cancer Phase II Trial
Learn how Veristat’s multidisciplinary team was able to work with the sponsor to solve challenges...
Bold Thinking that Delivers Results for RNA Therapies
Current advances in RNA-based therapies hold substantial promise in treating and preventing many...
On-Demand Webinar: Decentralized Trial Solutions for Complex Clinical Trials
Decentralized clinical trials (DCTs) are becoming increasingly popular to optimize patient...
Laying the Groundwork to Measure the Impact of Decentralized Clinical Trials (DCTs)
The Tufts CSDD Roundtable took place in November, and on behalf of Veristat, I was honored to...
Is it Possible to Gain Regulatory Approval Following a Single-Arm Study?
In this case study example - yes.
Veristat developed a thorough regulatory submission strategy and...
Planning the Way Forward in Neurodegenerative Disease Studies
Clinical trials involving gene therapies for the treatment of Central Nervous System (CNS)...